Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RIGL Rigel Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: RIGL
Price (delayed)
$18.9
Market cap
$337.79M
P/E Ratio
9
Dividend/share
N/A
EPS
$2.1
Enterprise value
$353.13M
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare
Highlights
RIGL's equity has soared by 159% YoY
The net income has surged by 113% since the previous quarter
The quick ratio has soared by 70% YoY but it has contracted by 5% from the previous quarter
The gross margin has contracted by 3.9% YoY
Key stats
What are the main financial stats of RIGL
Market
Valuations
Earnings
Shares outstanding
17.87M
Market cap
$337.79M
Enterprise value
$353.13M
Price to earnings (P/E)
9
Price to book (P/B)
18.18
Price to sales (P/S)
1.66
EV/EBIT
7.67
EV/EBITDA
7.29
EV/Sales
1.74
Revenue
$203.08M
Gross profit
$182.05M
Operating income
$43.93M
Net income
$37.18M
EBIT
$46.02M
EBITDA
$48.45M
Free cash flow
$35.43M
Per share
Balance sheet
Liquidity
EPS
$2.1
EPS diluted
$2.08
Free cash flow per share
$1.99
Book value per share
$1.04
Revenue per share
$11.4
TBVPS
$8.39
Total assets
$175.97M
Total liabilities
$157.41M
Debt
$61.07M
Equity
$18.57M
Working capital
$79.93M
Debt to equity
3.29
Current ratio
2.2
Quick ratio
1.78
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
23.9%
Gross margin
89.6%
Net margin
18.3%
Operating margin
21.6%
Return on assets
24.5%
Return on equity
N/A
Return on invested capital
60%
Return on capital employed
42.1%
Return on sales
22.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RIGL stock price
How has the Rigel Pharmaceuticals stock price performed over time
Intraday
2.33%
1 week
0.96%
1 month
15.46%
1 year
90.52%
YTD
12.37%
QTD
5.06%
Financial performance
How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$203.08M
Gross profit
$182.05M
Operating income
$43.93M
Net income
$37.18M
Gross margin
89.6%
Net margin
18.3%
The net income has surged by 113% since the previous quarter
RIGL's net margin has soared by 87% QoQ
RIGL's operating income has surged by 82% since the previous quarter
Rigel Pharmaceuticals's revenue has surged by 69% YoY and by 13% QoQ
Price vs fundamentals
How does RIGL's price correlate with its fundamentals
Growth
What is Rigel Pharmaceuticals's growth rate over time
Valuation
What is Rigel Pharmaceuticals stock price valuation
P/E
9
P/B
18.18
P/S
1.66
EV/EBIT
7.67
EV/EBITDA
7.29
EV/Sales
1.74
Rigel Pharmaceuticals's EPS has surged by 112% QoQ
RIGL's equity has soared by 159% YoY
Rigel Pharmaceuticals's revenue has surged by 69% YoY and by 13% QoQ
The stock's price to sales (P/S) is 41% less than its 5-year quarterly average of 2.8 but 11% more than its last 4 quarters average of 1.5
Efficiency
How efficient is Rigel Pharmaceuticals business performance
The return on assets has surged by 96% since the previous quarter
Rigel Pharmaceuticals's return on sales has surged by 54% QoQ
RIGL's return on invested capital has surged by 53% since the previous quarter
Dividends
What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RIGL.
Financial health
How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets is 12% more than its total liabilities
RIGL's current ratio has soared by 75% year-on-year and by 3.3% since the previous quarter
The quick ratio has soared by 70% YoY but it has contracted by 5% from the previous quarter
RIGL's equity has soared by 159% YoY
RIGL's debt to equity has shrunk by 82% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.